IL17RB and breast neoplasm: Further investigation showed that cancer cells in the TDLNs enhanced their malignancy by up‐regulating oncogenic receptor, IL‐17rb, in both syngeneic mouse breast tumor model and clinical patients (Figs 3A–C and 7A and B).